Epigene Labs’ Post

🚀 Excited to share that I’ll be representing Epigene Labs at the J.P. Morgan Healthcare Conference 2025! From January 13–16, our VP of Business Development, Kevin Cho, and I will be in San Francisco for this premier global gathering of biopharma leaders and innovators. 🌍💊 🔍 Why meet with us? At Epigene Labs, we’re unlocking insights for faster precision #oncology breakthroughs. Our mCUBE platform combines #AI and advanced #bioinformatics to transform fragmented cancer research data into cohesive, high-resolution disease atlases. Here’s what makes mCUBE stand out: 🌐 Multi-source: Access to 90,000+ patient sample profiles from 950+ datasets 🌐 Multi-omic: Integration of multiple layers of genomic information 🌐 Multi-cancer: Coverage of 30+ cancer types By streamlining scattered omic datasets into actionable insights, we help compress R&D timelines from months to days—potentially increasing success rates by up to 3X. 📩 Let’s connect to supercharge your precision oncology programs and gain a smarter, data-driven edge in #cancer research and drug development. Together, we can drive breakthroughs faster. 💡

Looking forward to participating in this timely discussion on where we are at in the war on cancer.

🌟 Inspiring Insights from the Cancer Diagnostics Panel at the Oncology Venture, Innovation & Partnering Summit! 🌟 Insightful panel organized by Mara Aspinall on Cancer Diagnostics, Screening, and Early Detection and moderated by Tom Miller, Founder & Managing Partner at GreyBird Ventures, LLC. The panel featured industry leaders and investors: Lisa Alderson, CEO of Adela, Inc. Anthony Chang, PhD, Founder & CEO of BAMF Health Alan Hirzel, Life Science Director and Investor, Former CEO of Abcam Darshana Zaveri, Founder and Managing Partner at Catalyst Health Ventures 🔑 Key Takeaway: Harnessing Multi-omics for Precision Medicine: The integration of multi-omics technologies is revolutionizing cancer diagnostics, enabling earlier detection and more personalized patient care. At Predicta Biosciences, we are deeply aligned with this approach as we develop next-generation diagnostic assays to advance precision medicine. #CancerDiagnostics #MultiOmics #PrecisionMedicine  #Innovation

#ASCO 2024 Topic Takeover 📣 🧬Empowering clinical labs to deploy genomics applications and Sponsored Testing Programs: SOPHiA DDM™ MaxCare Implementing a genomic application is complex and time-consuming, requiring proficiency at many levels. The SOPHiA DDM ™ MaxCare Program empowers teams to gain confidence in their results, establish workflow efficiency and meet quality standards, facilitating their self-validation and accreditation efforts. This program also offers comprehensive training and analytical performance assessment decreasing the time to adoption of #biomarker testing in clinical research. Read this press release on how we helped with the deployment of HRD testing in Spain which allowed for over 4,000 ovarian cancer samples to be analyzed. https://lnkd.in/gUsnkA9q ❗Get more out of ASCO 2024 and book a meeting with us to discuss our capabilities of decentralizing molecular testing. https://loom.ly/XlWi72E American Society of Clinical Oncology (ASCO) #ASCO24 #PrecisionOncology #AIinHealthcare #DeepLearning #DataDriveMedicine #Genomics #Oncology

If you're attending Biomarkers by Oxford Global's #BiomarkersEU24, let’s connect and explore how proteomics and our Proteograph technology could support biomarker discovery in your #oncology research. We invite you to: 🗓️ Join our partner presentation with Bruce Wilcox, Ph.D, CTO, PrognomiQ Inc. He will share breakthrough insights into how he leveraged data from multiple 'omics methods to uncover hard-to-find #biomarkers in a lung cancer study - with #proteomics playing a leading role! Date: Mon., Sept. 30. Time: 14:10-14:30pm. Location: Conference Room 3. 📈 Visit the Seer team at Booth 16 and learn how the #Proteograph's unbiased, automated workflow is enabling researchers to study biofluids in depth to identify thousands of proteins, including peptide-level variants. It's also an opportunity to access our brand-new Oncology Research Guide full of data and industry and academia applications. For more information: https://lnkd.in/g3Zi77cs #biomarkerdiscovery #biomarkerresearch #biomarkerinnovation #precisiononcology #immunotherapies #scienceandinnovation

👋 Hello to all our new followers! If you're new here, here's a snapshot of what we do… 👐 At Carcinotech, our mission is to accelerate the development of cancer treatments, ensuring that individuals facing the disease can access the best options for improved survival and quality of life. To do this, we've pioneered the development of 3D-bioprinted tumours as a tool for drug research and development. ⚕️ Our proprietary bioprinting methodology allows us to engineer tumours derived from human biopsies, achieving an impressive 99% similarity to the native tumour. This results in a highly effective model for predicting clinical outcomes, helping to lower attrition rates in drug development. 🚀 Our technology is not just a leap forward for cancer research; it’s a game-changer. By providing a more accurate and predictive cancer model, we reduce reliance on animal testing and deliver significant time and cost savings to drug developers. 👩🔬 But we don’t stop at manufacturing tumours. Our expert scientific team offers a comprehensive range of assays to evaluate therapeutic performance on our models, enabling informed decision-making throughout the drug development cycle. 🌟 Reach out to us today to learn how Carcinotech can support your research: https://lnkd.in/eWrrHpB8 #CancerResearch #OncologyInnovation #Biotechnology #TissueEngineering

Check out the exciting new developments from Bio-Rad in the oncology space, including new methylation assays, IVDR certification of our BCR-ABL assay, and collaborations with leading institutions to drive clinical research. #ddPCR #PrecisionOncology #Oncology #AMPATH24

Are you looking for a Comprehensive Genomic Profiling Solution that will enable laboratory transformation? Considering an alternative to TSO500? At OncoDNA we create blended teams with our customers focused on ensuring a high quality genomics testing service for oncologists and their patients. If you are looking for references please contact me as we can put you in touch with exisiting customers in the Europe, UK, Israel and beyond... Hear directly what laboratory leaders say about OncoDNA and the OncoDEEP Kit. #CGP hashtag #genomics hashtag #oncology hashtag #clinicalscientists hashtag #cancer hashtag #oncoDEEP

📣 Live from AMP 2024 in Vancouver! 🇨🇦 The SeqOne team is thrilled to meet you at Booth 526 Join us to explore how we're revolutionizing oncology bioinformatics with our cutting-edge solutions: ▶️ SomaCGP: Unlock complex multigenetic alterations—TMB, MSI, fusions, SNPs, and more—in a single workflow for streamlined analysis. ▶️ SomaHRD: Assess genomic instability from sWGS to personalize ovarian cancer treatment strategies. ▶️ SomaVar: High-precision variant calling for Solid Tumors and Hematologic Malignancies, supporting both hybrid capture and amplicon technologies. Our platform simplifies complex genomic data interpretation for faster, more precise clinical decisions in oncology. Let's discuss how our advanced bioinformatics tools can enhance your workflow and improve patient care in precision oncology! 🧬 See you at Booth 526! 👋 #AMP2024 #Oncology #NGS #PrecisionMedicine #Bioinformatics #Genomics #PersonalizedMedicine

Innate Immunity – The next big thing in cancer immunotherapy?! We’ve produced several videos for immuno-oncology therapies. And I want to learn more about future treatments focusing on the innate immune system. Here’s what I want to discover: - How innate immunity could transform cancer therapy - Its potential to reach more patients than current treatments - New research driving this shift Join me and sign up for the webinar. Thanks Arthur Krieg